BYLINE: Noah Fromson

Newswise — As the American Heart Association Scientific Sessions 2022 kicks off this weekend, many experts will be presenting late-breaking science that features the most highly anticipated breakthroughs of the year. As they present, we have an expert in vascular medicine from University of Michigan Health who is available to comment on several findings:

Geoffrey D. Barnes, M.D. – cardiologist at the University of Michigan Health Frankel Cardiovascular Center, associate professor of internal medicine at U-M Medical School

  • Dr. Barnes is a cardiologist who specializes in vascular medicine. His health services research interests focus on safe and effective delivery of anticoagulation care, particularly with patients with atrial fibrillation and venous thromboembolism. He also is a national leader in the care of patients with peripheral artery disease with a focus on improving medical management. He is program director of the Michigan Anticoagulation Quality Improvement Initiative, a Blue Cross Blue Shield of Michigan sponsored collaborative QI consortium.  

Barnes is available to speak about:

  • Preventing Limb Loss Through Vascular Interventions and Venous Therapies (11/7 at 8 a.m. CT)
    • BEST-CLI (Clinical) - Best Endovascular versus Best Surgical Therapy for Patients with Chronic Limb Threatening Ischemia - Clinical Results 
    • BEST-CLI (QOL) – Best Endovascular versus Best Surgical Therapy for Patients with Chronic Limb Threatening Ischemia - Quality of Life Analyses  
    • PREVENT-HD – Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients with Covid-19: Primary Results of the PREVENT-HD Randomized Clinical Trial
    • IMPROVE – A Multicenter Clustered Randomized Trial of a Universal Electronic Health Record-Based Venous Thromboembolism Risk Assessment Model as Integrated Clinical Decision Support for Prevention of Thromboembolism in Hospitalized Medically-Ill Patients
  • Treating Atrial and Supraventricular Arrhythmias (11/7 at 11 a.m. CT)
    • ENHANCE-AF – Clinical Trial to Evaluate an Atrial Fibrillation Stroke Prevention Shared Decision-Making Pathway

MEDIA CONTACT
Register for reporter access to contact details
TYPE OF ARTICLE
Expert Pitch
SECTION
CHANNELS
Cardiovascular Health Heart Disease Scientific Meetings
KEYWORDS
Vascular Medicine Anticoagulant Vascular Interventions Atrial Fibrillation Limb Threatenin American Heart Association american heart association scientific sessions
COMMENTS | COMMENTING POLICY